PL3256594T3 - Ulepszone dostarczanie cząstek wirusa do prążkowia i kory - Google Patents

Ulepszone dostarczanie cząstek wirusa do prążkowia i kory

Info

Publication number
PL3256594T3
PL3256594T3 PL16714066T PL16714066T PL3256594T3 PL 3256594 T3 PL3256594 T3 PL 3256594T3 PL 16714066 T PL16714066 T PL 16714066T PL 16714066 T PL16714066 T PL 16714066T PL 3256594 T3 PL3256594 T3 PL 3256594T3
Authority
PL
Poland
Prior art keywords
strain
circle
virus particles
improved delivery
delivery
Prior art date
Application number
PL16714066T
Other languages
English (en)
Inventor
Lisa M. Stanek
Lamya Shihabuddin
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL3256594T3 publication Critical patent/PL3256594T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16714066T 2015-02-10 2016-02-09 Ulepszone dostarczanie cząstek wirusa do prążkowia i kory PL3256594T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562114544P 2015-02-10 2015-02-10
US201562220997P 2015-09-19 2015-09-19
PCT/US2016/017210 WO2016130591A2 (en) 2015-02-10 2016-02-09 Enhanced delivery of viral particles to the striatum and cortex
EP16714066.4A EP3256594B1 (en) 2015-02-10 2016-02-09 Enhanced delivery of viral particles to the striatum and cortex

Publications (1)

Publication Number Publication Date
PL3256594T3 true PL3256594T3 (pl) 2022-02-14

Family

ID=56614902

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16714066T PL3256594T3 (pl) 2015-02-10 2016-02-09 Ulepszone dostarczanie cząstek wirusa do prążkowia i kory

Country Status (27)

Country Link
US (3) US20190111157A1 (pl)
EP (3) EP4219728A3 (pl)
JP (4) JP6928558B2 (pl)
KR (2) KR102863734B1 (pl)
CN (2) CN107530447A (pl)
AU (3) AU2016219398A1 (pl)
BR (1) BR112017017037A2 (pl)
CA (1) CA2976082A1 (pl)
CL (1) CL2017002028A1 (pl)
CR (1) CR20170407A (pl)
DK (1) DK3256594T3 (pl)
EA (1) EA201791803A1 (pl)
ES (1) ES2904504T3 (pl)
HU (1) HUE057272T2 (pl)
IL (4) IL296466B2 (pl)
LT (1) LT3256594T (pl)
MX (2) MX388264B (pl)
NZ (1) NZ772772A (pl)
PH (1) PH12017501436A1 (pl)
PL (1) PL3256594T3 (pl)
PT (1) PT3256594T (pl)
RS (1) RS62811B1 (pl)
SG (3) SG10201907399RA (pl)
SI (1) SI3256594T1 (pl)
TN (1) TN2017000353A1 (pl)
TW (1) TWI730952B (pl)
WO (1) WO2016130591A2 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
NZ772772A (en) * 2015-02-10 2024-12-20 Genzyme Corp Enhanced delivery of viral particles to the striatum and cortex
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
EP4491733A3 (en) 2015-04-23 2025-03-26 University of Massachusetts Modulation of aav vector transgene expression
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
BR112018006074A2 (pt) 2015-09-24 2018-10-09 Biomarin Pharm Inc vetores de fator viii de vírus adeno-associado, partículas virais associadas e formulações terapêuticas compreendendo as mesmas
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
BR112018073472A2 (pt) 2016-05-18 2019-08-27 Voyager Therapeutics, Inc. composições e métodos de tratamento da doença de huntington
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
JP7059285B2 (ja) * 2016-09-30 2022-04-25 エステベ プアルマセウティカルス， エッセ．ア． ムコ多糖症の治療のためのアデノ随伴ウイルスベクター
US20210108197A1 (en) * 2017-03-31 2021-04-15 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Shrna expression cassette, polynucleotide sequence carrying same, and application thereof
WO2018191450A2 (en) 2017-04-14 2018-10-18 National Taiwan University Hospital Gene therapy for aadc deficiency
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
WO2019028306A2 (en) 2017-08-03 2019-02-07 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
JP2021520811A (ja) 2018-04-13 2021-08-26 ユニバーシティ オブ マサチューセッツ ヘキソサミニダーゼアルファおよびベータサブユニットをコードしているバイシストロニックａａｖベクターならびにその使用
AU2019268330A1 (en) 2018-05-15 2020-11-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
CN113528510A (zh) * 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
KR20210087462A (ko) 2018-10-05 2021-07-12 유니버시티 오브 매사추세츠 Gm1 및 gm2 강글리오시드증의 치료를 위한 raav 벡터
SG11202104295UA (en) * 2018-11-14 2021-06-29 Regenxbio Inc Gene therapy for neuronal ceroid lipofuscinoses
BR112021015817A2 (pt) * 2019-02-22 2021-10-13 The Trustees Of The University Of Pennsylvania Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn
EP3983077A4 (en) * 2019-06-17 2023-12-20 Alnylam Pharmaceuticals, Inc. DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM
WO2021007382A1 (en) * 2019-07-09 2021-01-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
WO2021016505A1 (en) * 2019-07-24 2021-01-28 Voyager Therapeutics, Inc. Compositions and methods for treating huntington's disease
US12442017B2 (en) 2020-03-02 2025-10-14 National University Corporation Gunma University Microglial selective gene expression vector
EP4093859A4 (en) * 2020-03-11 2023-06-14 Remotor Therapeutics, Inc. Methods and materials for disseminating a protein throughout the central nervous system
JP2023532944A (ja) * 2020-06-30 2023-08-01 セキラス ユーケー リミテッド 水中油型エマルジョンアジュバントの低温濾過
AU2022212922A1 (en) * 2021-01-27 2023-08-17 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
WO2023113806A1 (en) 2021-12-16 2023-06-22 Affinia Therapeutics, Inc. Recombinant aav for treatment of neural disease
WO2022221193A1 (en) 2021-04-12 2022-10-20 Affinia Therapeutics Inc. Recombinant aav for treatment of neural disease
CN120187407A (zh) * 2021-12-15 2025-06-20 健达九州(北京)生物科技有限公司 重组aav载体及其用途
US20250333758A1 (en) * 2021-12-15 2025-10-30 Genans Biotechnology Co., Ltd Microglia having car and use thereof
EP4605410A1 (en) 2022-10-19 2025-08-27 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
WO2025151454A1 (en) * 2024-01-08 2025-07-17 AskBio Inc. Method or system of infusing and/or predicting an infusate volume
WO2025227063A1 (en) 2024-04-26 2025-10-30 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US5735815A (en) 1993-07-26 1998-04-07 Sentinel Medical, Inc. Method of using fluid jet surgical cutting tool
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
PT1080202E (pt) 1998-05-27 2006-05-31 Avigen Inc Distribuicao de vectores aav codificando aadc intensificada por conveccao
ATE403715T1 (de) 1999-08-09 2008-08-15 Targeted Genetics Corp Erhöhung der expression einer einzelsträngigen, heterologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
WO2003004660A1 (en) 2001-07-03 2003-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
CN103555677B (zh) 2001-11-13 2018-01-30 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
GB2389791B (en) 2002-04-30 2006-12-13 Steven Gill Implantable drug delivery pump
ES2521682T3 (es) 2003-05-21 2014-11-13 Genzyme Corporation Procedimientos para producir preparaciones de viriones de AAV recombinantes sustancialmente exentas de cápsidas vacías
EP2572661B1 (en) 2004-10-05 2019-11-20 Genzyme Corporation Stepped cannula
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
PT2420256T (pt) * 2005-05-02 2016-09-13 Genzyme Corp Terapia genética para distúrbios neurometabólicos
AU2006283189B2 (en) 2005-08-23 2013-01-31 The Regents Of The University Of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
PT2019683T (pt) 2006-04-25 2017-03-17 Univ California Administração de fatores de crescimento para o tratamento de distúrbios do snc
US20070259031A1 (en) 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
RU2442617C2 (ru) 2007-05-17 2012-02-20 Медженезиз Терапьютикс Инк. Конвекционный доставляющий катетер со съемным элементом жесткости и способ его применения
CA2751266A1 (en) * 2009-01-29 2010-08-05 Krystof Bankiewicz Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
HUE040636T2 (hu) 2009-06-16 2019-03-28 Genzyme Corp Javított eljárások rekombináns AAV-vektorok tisztítására
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
ES2739804T3 (es) * 2011-02-12 2020-02-04 Univ Iowa Res Found Compuestos terapéuticos
ES2724800T3 (es) 2011-02-17 2019-09-16 Univ Pennsylvania Composiciones y métodos para alterar la especificidad de tejido y mejorar la transferencia génica mediada por AAV9
WO2015168666A2 (en) * 2014-05-02 2015-11-05 Genzyme Corporation Aav vectors for retinal and cns gene therapy
NZ772772A (en) * 2015-02-10 2024-12-20 Genzyme Corp Enhanced delivery of viral particles to the striatum and cortex
CN111417231A (zh) 2019-01-04 2020-07-14 青岛海尔股份有限公司 电磁波发生系统及具有该电磁波发生系统的加热装置

Also Published As

Publication number Publication date
BR112017017037A2 (pt) 2018-04-10
EP4219728A2 (en) 2023-08-02
IL253894B (en) 2021-08-31
AU2025201381A1 (en) 2025-03-20
US12465657B2 (en) 2025-11-11
JP6928558B2 (ja) 2021-09-01
MX2017010370A (es) 2017-12-14
US20220395586A1 (en) 2022-12-15
TWI730952B (zh) 2021-06-21
JP2021178861A (ja) 2021-11-18
DK3256594T3 (da) 2022-01-24
TW201642909A (zh) 2016-12-16
IL313840A (en) 2024-08-01
KR20240010539A (ko) 2024-01-23
WO2016130591A3 (en) 2016-11-10
CN116019934A (zh) 2023-04-28
AU2016219398A1 (en) 2017-09-28
IL296466A (en) 2022-11-01
EP4023758A1 (en) 2022-07-06
SG10201912926VA (en) 2020-02-27
CN107530447A (zh) 2018-01-02
EA201791803A1 (ru) 2017-11-30
NZ772772A (en) 2024-12-20
JP2018506585A (ja) 2018-03-08
SG10201907399RA (en) 2019-09-27
AU2022204583A1 (en) 2022-07-21
EP3256594B1 (en) 2021-10-20
JP2025060823A (ja) 2025-04-10
CL2017002028A1 (es) 2018-04-13
SI3256594T1 (sl) 2022-07-29
US20190111157A1 (en) 2019-04-18
IL296466B1 (en) 2024-07-01
CR20170407A (es) 2017-11-14
NZ735290A (en) 2023-10-27
IL285060A (en) 2021-08-31
IL285060B2 (en) 2023-02-01
ES2904504T3 (es) 2022-04-05
CA2976082A1 (en) 2016-08-18
US20260048149A1 (en) 2026-02-19
RS62811B1 (sr) 2022-02-28
MX2021004294A (es) 2021-06-04
HK1246340A1 (zh) 2018-09-07
EP3256594A2 (en) 2017-12-20
LT3256594T (lt) 2022-02-10
JP2023058630A (ja) 2023-04-25
IL285060B (en) 2022-10-01
IL253894A0 (en) 2017-10-31
KR102625784B1 (ko) 2024-01-15
PH12017501436A1 (en) 2018-01-15
SG11201706445SA (en) 2017-09-28
EP4219728A3 (en) 2023-08-23
WO2016130591A2 (en) 2016-08-18
PT3256594T (pt) 2022-01-18
KR20170110718A (ko) 2017-10-11
MX388264B (es) 2025-03-19
IL296466B2 (en) 2024-11-01
HUE057272T2 (hu) 2022-04-28
TN2017000353A1 (en) 2019-01-16
KR102863734B1 (ko) 2025-09-25

Similar Documents

Publication Publication Date Title
PL3256594T3 (pl) Ulepszone dostarczanie cząstek wirusa do prążkowia i kory
IL280905A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
ZA201703163B (en) Rna guided eradication of human jc virus and other polyomaviruses
SG11201606624WA (en) Antibody moleules to dengue virus and uses thereof
PT3221363T (pt) Anticorpos contra cd73 e utilizações dos mesmos
MA40595A (fr) Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
IL249061A0 (en) Combination, composition, and method of administering the combination or composition to animals
IL286265A (en) A new tilapia virus and its uses
IL247870A0 (en) The hemagglutinin antibodies against influenza b virus and methods of use
SI3718565T1 (sl) Cepiva za respiratorni virus
ZA201700165B (en) Influenza virus vaccines and uses thereof
IL252026B (en) Humanized anti-complement factor c1q antibodies and uses thereof
PT3274370T (pt) Anticorpos anti-ceacam6 e utilizações dos mesmos
PT3119431T (pt) Anticorpos antagonistas dirigidos contra o peptídeo relacionado com o gene da calcitonina e métodos de utilização dos mesmos
PL3198009T3 (pl) Onkolityczne wirusy nowotworowe i sposoby zastosowania
IL252418B (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
SG11201610443WA (en) Influenza virus vaccines and uses thereof
IL259202A (en) Modified immune cells and uses thereof
PL3154515T3 (pl) Udoskonalenia kompozycji donosowych i sposób ich stosowania
IL249582A0 (en) Use of materials incorporating microparticles for avoiding the proliferation of contaminants
IL258856A (en) Solabegron zwitterion and uses thereof
HUE055330T2 (hu) Javított aktivitású exoglükanázok variánsai és alkalmazásaik
SG11201704942QA (en) Dengue virus vaccine compositions and methods of use thereof
PL3158076T3 (pl) Warianty egzoglukanaz o polepszonej aktywności i ich zastosowania
ITUB20152292A1 (it) Accorgimenti per incastonare pietre e solitari.